skip to Main Content

Kundranda Covers Key Trials Generating Excitement in Pancreatic Cancer Paradigm

Kundranda Covers Key Trials Generating Excitement in Pancreatic Cancer Paradigm
Although the pancreatic cancer treatment paradigm has suffered from a period of stagnation, several ongoing research efforts are being made to improve outcomes for patients, according to Madappa Kundranda, MD, PhD, who added that trials like NAPOLI-3 and AVENGER 500 are generating excitement in the space.

“When I reflect on the pancreatic cancer treatment landscape, it has been a bit disappointing, but we have worked through these disappointments, ever since 1997 when we didn’t have a standard of care,” said Kundranda. “That was when we [only] had gemcitabine, a single agent. Read more . . .


Back To Top